Sign in
Taking people in United StatesNo phase

Long-term safety follow-up of people who received gene-modified immune cells

Follows people with rheumatoid arthritis or hidradenitis suppurativa for long-term safety after treatment.

Key facts

Who runs it
Sonoma Biotherapeutics, Inc.
Where
Aurora, Boston, Chicago, Durham, Houston, Minneapolis, San Francisco, and Stanford, United StatesSee the 10 sites
Trial code
Registry title
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
Status
Recruiting
People taking part
36 people, planned
Started
22 Jul 2025
Expected to end
Dec 2040
Type of study
Observational
Treatments tested
  • Long Term Safety Monitoring Procedures
Record updated
16 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people who already received a gene-modified Treg therapy from Sonoma Biotherapeutics in an earlier trial. It follows them over time to watch for late side effects.

Age
18 Years to 71 Years
Sex
All sexes can join.
Earlier treatment
Must have received at least 1 dose of a Sonoma Biotherapeutics, Inc. gene-modified Treg therapy in an earlier parent treatment protocol.

Main reasons for not taking part

  • Taking part is not in the person's interest, in the opinion of the Investigator

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Subject was previously administered at least 1 dose of a Sonoma Biotherapeutics, Inc. gene-modified Treg therapeutic in a prior parent treatment protocol
  • Subject understands the purpose and risks of the study and is willing to provide written informed consent
  • Subject is willing to comply with all study procedures for the follow-up period

Who cannot take part

  • Participation in the study is not in the subject's best interest, in the opinion of the Investigator

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 71 years old?

Where in United States

  • University of ColoradoAurora, United StatesContact: Jennifer SeifertTaking people
  • Brigham and Women's HospitalBoston, United StatesContact: James P SullivanTaking people
  • Massachusetts General HospitalBoston, United StatesContact: Daniella CookTaking people
  • Tufts UniversityBoston, United StatesContact: Andreas KleinTaking people
  • Northwestern UniversityChicago, United StatesContact: John SeagristTaking people
  • Duke UniversityDurham, United StatesContact: Laura Van AlthuisNot yet recruiting
  • The University of Texas MD Anderson Cancer CenterHouston, United StatesContact: Stacie StutteNot yet recruiting
  • University of MinnesotaMinneapolis, United StatesContact: Irmina WallanderNot yet recruiting
  • UCSF Medical CenterSan Francisco, United StatesContact: Alex CarvidiTaking people
  • Stanford Medical CenterStanford, United StatesContact: Uma Vilas AyachitTaking people

About the trial

What the trial wants to find out

To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.

The group in the trial

  • Participants exposed to SBT777101 Treg cell therapy

    Participants exposed to SBT777101 during the original Phase 1 clinical safety study (NCT06201416, NCT06361836)

    Treatment: Long Term Safety Monitoring Procedures

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
Plain-language title
Long-term safety follow-up of people who received gene-modified immune cellsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07123038, who can take part
Record updated
16 April 2026